Navigation Links
An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes

clinical illness should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. The reported incidence of lactic acidosis in patients receiving metformin hydrochloride is very low (approximately 0.03 cases/1000 patient-years, with approximately 0.015 fatal cases/1000 patient-years). When lactic acidosis occurs, it is fatal in approximately 50 percent of cases.

Expanding clinical development program for sitagliptin family

Merck's clinical development program for sitagliptin is robust and continues to expand with 47 studies completed or under way, and nine more studies set to begin this year. There have been more than 7,600 patients in the Company's clinical studies with about 4,700 of these patients, being treated with sitagliptin. Additionally, about 1,900 patients have been treated with sitagliptin for more than a year.

Merck's Commitment to Type 2 Diabetes

Journey for Control(TM) is Merck's comprehensive educational initiative designed to enlighten, inspire, and empower patients with diabetes by helping them make the necessary lifestyle modifications that lead to improved self-management. The program includes resources for physicians, diabetes educators, patients and health plans; all created with a focus on improving diabetes education. The Merck Journey for Control Program is proud to sponsor the U.S. Diabetes Conversation Maps, an interactive program that combines visual learning techniques and active dialogue between patients and healthcare professional to engage patients in sustainable behavior change.

The U.S. Diabetes Conversation Maps will provide physicians and diabetes educators with a uniquely powerful way to engage patients in conversations to help support behavior changes that can make a critical difference in treatment outcomes. Content for the U.S. Diabetes Conversation Map was developed and reviewed by the ADA and the program was launched in June at the ADA 67th Annual Scientific Sessions in Chicago
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:9/15/2014)... /PRNewswire-iReach/ -- Asthma is a chronic inflammatory lung ... most commonly starts in childhood. It is a ... airways, leading to airflow limitation and airway hyper-responsiveness ... endogenous and exogenous irritants. Exposure to irritants instigates ... the airways, tightening of the respiratory muscles, and ...
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire-iReach/ -- MedicOne Medical Response, ... services, has been selected by Inc. Magazine as ... America. Photo - http://photos.prnewswire.com/prnh/20140914/145997 ... list identifies successful, privately-held companies with the largest ... Response, one of only two ambulance companies to ...
(Date:9/15/2014)... Nev. , Sept. 15, 2014 PDL BioPharma, ... that it has paid the September 12, 2014, regular quarterly ... owning shares of PDL as of September 5, 2014, the ... PDL BioPharma manages a portfolio of patents and ... antibody humanization patents and license agreements with various biotechnology ...
Breaking Medicine Technology:Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3PDL BioPharma Completes Regular Quarterly Dividend Payment 2
... to Prevent,and Reverse Atherosclerotic Heart Disease, EMERYVILLE, Calif., ... drug discovery and development company, announced,today the first ... in animals through the pathway known as reverse ... by which excess,cholesterol can be removed from tissues ...
... 14, 2007 - Acceleron Pharma,Inc., a biopharmaceutical ... metabolic and cancer-related,diseases, today announced results of ... ability of the compound to increase,muscle mass ... murine models of,muscular dystrophy. ACE-031 inhibits negative ...
Cached Medicine Technology:KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 3Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 2Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 3
(Date:9/15/2014)... 2014 Crosley Law Firm is proud to ... have been named to the list of Super Lawyers in ... of personal injury law. , Before receiving the designation ... selection process. First, they must come highly recommended by a ... noteworthy achievement during the past year by obtaining certain honors, ...
(Date:9/15/2014)... September 16, 2014 “Advanced First Aid for ... author Frank O’ Connor leads readers from occupational first aid ... first aid without any difficulty. There are over 165 photographs ... skill sets. , This book is an ideal reference ... course manual. It is in essence three books in one. ...
(Date:9/15/2014)... the University of Copenhagen have gained new knowledge ... The findings have recently been published in the ... The defining symptoms of Parkinson,s disease are slow ... no cure for the condition, so it is ... to shed some light on this terrible disruption ...
(Date:9/15/2014)... 2014)The Global Health Innovative Technology Fund (GHIT Fund), ... Japanese know-how and investment to the global fight ... totaling US$15.3 million to speed the development of ... diseasesmalaria, dengue and Chagas disease. The announcement marks ... since November 2013totaling $33.5 millionaimed at diseases that ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 College of Osteopathic ... recently sat in the lobby of Western University of Health ... Gomez. He asked Gomez about his medications, his blood pressure ... “He’s helping me a lot. He’s a good man,” Gomez ... student doctor and patient are part of the Longitudinal Chronic ...
Breaking Medicine News(10 mins):Health News:Thomas A. Crosley and R. Andrew Rodriguez Named 2014 Super Lawyers 2Health News:Frank O'Connor's new book explains importance of occupational and advanced first aid 2Health News:Researchers debunk myth about Parkinson's disease 2Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 2Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 3Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 4Health News:Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases 5Health News:COMP Takes the Long View of Health Care 2Health News:COMP Takes the Long View of Health Care 3Health News:COMP Takes the Long View of Health Care 4
... collaboration between researchers at the Salk Institute for Biological ... the tumor suppressor p53, long thought of as the ... cancer-causing mutations. It may also prevent established cancer cells ... serving as a "Guardian against Genome Reprogramming." The ...
... St. Louis and a woman in New Hampshire have received ... program of the Organ Procurement and Transplantation Network (OPTN) that ... candidates with living donors. Both recipients Ken Crowder of ... loved ones who were willing to donate a kidney but ...
... discrimination among Mexican and Mexican American students from Phoenix-area ... stress when trying to acculturate with mainstream U.S. culture, ... experienced acculturation stress related to discrimination, they were at ... The study is in the December issue of ...
... , MONDAY, Dec. 13 (HealthDay News) -- A federal judge ... unconstitutional, saying the federal government has no authority to require ... a cornerstone of the new legislation, signed into law in ... not unexpected, and both supporters and opponents of the legislation ...
... million men and women ages 50 to 64 stand ... that expand access to affordable health insurance, assure that ... insurers from denying coverage or charging higher premiums to ... limits in health insurance policies, according to a new ...
... the activity of genes direct changes to the DNA ... genes are switched on and off, called epigenetic means. Tumor-suppressor ... for the cancerous growth of cells. Researchers at the ... on a genome-wide scale in cases of ovarian cancer. ...
Cached Medicine News:Health News:The stemness of cancer cells 2Health News:The stemness of cancer cells 3Health News:2 people receive kidney transplants in pilot program using CMU software 2Health News:2 people receive kidney transplants in pilot program using CMU software 3Health News:Drug use and discrimination among Phoenix area Mexican heritage youth 2Health News:Drug use and discrimination among Phoenix area Mexican heritage youth 3Health News:Federal Judge Strikes Down Health Reform Law 2Health News:Federal Judge Strikes Down Health Reform Law 3Health News:18.3 million baby boomers could benefit from the Affordable Care Act 2Health News:18.3 million baby boomers could benefit from the Affordable Care Act 3Health News:18.3 million baby boomers could benefit from the Affordable Care Act 4Health News:Ovarian cancer advances when genes are silenced 2
Cloward cervical retractor. Size 18 mm....
Large, removable blades, length 242 mm, (9 1/2"). Function: tissue retracting....
Toothed Pituitary IVD Rongeurs, 8 length 200 mm....
Suitable for children and adults. New mechanical design of the skull pin holder and the clamp base ensures improved rigid skull fixation....
Medicine Products: